Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bregenz – page 17

211 clinical trials in Bregenz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bregenz at a glance
211
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

211 trials in Bregenz

Open in trial search

Pruritus+1

Not recruiting

Study on the Effectiveness and Safety of Difelikefalin for Adults with Moderate-to-Severe Itching from Notalgia Paresthetica

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Difelikefalin
  • Sponsor:Cara Therapeutics Inc.

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pehero
  • Sponsor:Arctic Bioscience AS

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen - Cilag International

Study Comparing Chemotherapy with Nivolumab to Chemotherapy Alone for Patients with Resectable Non-small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Adenocarcinoma gastric+2

Not recruiting

Study of DKN-01 and Tislelizumab with Chemotherapy for Adults with Advanced Gastric or Gastroesophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Leap Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bregenz

What the registry says about research in the country

01 Pediatric Rheumatology

Research focusing on Juvenile Idiopathic Arthritis (JIA), investigating innovative treatment approaches for young patients aged 1-17 years. These clinical trials aim to evaluate new therapeutic options for managing childhood arthritis.

  • Pediatric Arthritis Management
  • Early Intervention Strategies
  • Treatment Safety in Children

Studies are evaluating the effectiveness of baricitinib as a potential treatment option, with particular attention to safety profiles in pediatric populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.